0K3W.L StockTwits Mentions

Track 0K3W.L's AI-powered predictions, market trends, and investment insights.

0K3W.L AI Prediction 0K3W.L Sentiment 0K3W.L Reddit

Mock Tradesimulated, no real money

You don't hold 0K3W.L in your mock portfolio yet.

0K3W.L StockTwits Mentions

Track 0K3W.L's AI-powered predictions, market trends, and investment insights.

0K3W.L AI Prediction 0K3W.L Sentiment 0K3W.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-2.0%

Price (7d)-5.4%

Volume vs avg0.3x

Volatility vs normal1.2x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 2K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$3.66 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

0K3W.L AI Stock Analysis

Financial Performance

bearish

Myriad Genetics is currently unprofitable, as reflected in its negative EPS and negative P/E ratio. The valuation metric (P/E of -56.24) suggests investors are paying a high price relative to current losses, implying expectations for a turnaround that has yet to materialize. Without evidence of improving margins or a clear path to sustained profitability, the financial profile remains weak.

Negative EPS of -0.11 indicates the company is loss-making rather than generating net income.
A P/E ratio of -56.24 underscores that the stock is being valued despite ongoing losses, which heightens execution and turnaround risk.
Lack of visible profitability pressures key ratios such as net margin and return on equity, pointing to an overall challenged financial performance until earnings improve.

Stock Price & Technicals

bearish

The stock has declined 16% over the last month and trades far below its 200-day moving average, signaling a pronounced downtrend. An RSI of 45.23 is neutral to slightly weak, indicating neither oversold capitulation nor strong buying momentum. Overall, price action and long-term technicals lean clearly negative.

Current price of $6.13 is dramatically below the 200-day moving average of $20.78, reflecting a sustained long-term downtrend and prior significant drawdown.
A 16% decline over the past month points to recent selling pressure and weak near-term sentiment.
RSI at 45.23 is below the 50 midpoint, suggesting mildly bearish momentum without reaching oversold levels that might signal an imminent technical rebound.

Alternative Data Signals

neutral

Alternative data for Myriad Genetics is largely flat, with web traffic and most social media followings showing minimal growth or slight declines. This suggests stable but not expanding brand engagement or customer interest. The signals are not strongly negative, but they also do not support a growth or re-acceleration narrative.

Website traffic at ~206,688 monthly visitors is flat month over month (0.0% growth), indicating no recent acceleration in top-of-funnel interest.
Social channels show very modest changes: Instagram followers up 0.3% in 90 days, while Facebook followers declined by 0.1%, and Twitter/X, YouTube, and web traffic are flat.
LinkedIn following of 103,137 is relatively strong in absolute terms, suggesting a solid professional footprint, but the lack of recent growth data tempers its near-term bullish significance.

Conclusion

bearish

Myriad Genetics currently presents a challenging investment profile, with unprofitable operations, a negative P/E, and a stock price deeply below its long-term moving average. Alternative data is broadly stable rather than improving, offering little evidence of near-term demand acceleration or renewed investor enthusiasm. Overall, the balance of evidence points to a bearish outlook until there is clear progress on profitability and a reversal in price momentum.

Unprofitable financials and a deeply discounted price versus the 200-day moving average signal elevated risk and weak market confidence.
Flat to slightly mixed alternative data (web traffic and social metrics) does not yet support a strong turnaround or growth narrative.

AI Score

Hold

Alternative5

Fundamental2

Technical4

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold 0K3W.L in your mock portfolio yet.